Related Experiment Videos
Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with
Tobin J Cammett1, Li Luo, Zheng-yu Peng
1Department of Biochemistry, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA.
Abstract:
Cyclin-dependent kinase inhibitor p16(INK4a) is the founding member of the INK4 family of tumor suppressors capable of arresting mammalian cell division. Missense mutations in the p16(INK4a) gene (INK4a/CDKN2A/MTS1) are strongly linked to several types of human cancer. These mutations are evenly distributed throughout this small, ankyrin repeat protein and the majority of them disrupt the native secondary and/or tertiary structure, leading to protein unfolding, aggregation and loss of function. We report here the use of multiple stabilizing substitutions to increase the stability of p16(INK4a) and furthermore, to restore Cdk4 binding activity of several defective, cancer-related mutant proteins. Stabilizing substitutions were predicted using four different techniques. The three most effective substitutions were combined to create a hyperstable p16(INK4a) variant that is 1.4 kcal/mol more stable than wild-type. This engineered construct is monomeric in solution with wild-type-like secondary and tertiary structure and cyclin-dependent kinase 4 binding activity. Interestingly, these hyperstable substitutions, when combined with oncogenic mutations R24P, P81L or V126D, can significantly restore Cdk4 binding activity, despite the divergent features of each destabilizing mutation. Extensive biophysical studies indicate that the hyperstable substitutions enhance the binding activity of mutant p16 through several different mechanisms, including an increased amount of secondary structure and thermostability, reduction in exposed hydrophobic surface(s) and/or a reduced tendency to aggregate. This apparent global suppressor effect suggests that increasing the thermodynamic stability of p16 can be used as a general strategy to restore the biological activity to defective mutants of this important tumor suppressor protein.
Insights
Engineered hyperstable p16(INK4a) protein variants regain tumor suppressor function. Stabilizing mutations restore Cdk4 binding to cancer-associated p16 mutants, suggesting a general strategy for enhancing protein stability and activity.
Area of Science:
- Biochemistry
- Molecular Biology
- Structural Biology
Background:
- p16(INK4a) is a tumor suppressor that arrests cell division.
- Missense mutations in p16(INK4a) are linked to human cancers and often disrupt protein structure and function.
- Restoring the function of mutant p16(INK4a) is crucial for cancer therapy.
Purpose of the Study:
- To engineer a hyperstable p16(INK4a) variant with enhanced stability and Cdk4 binding activity.
- To investigate if stabilizing substitutions can restore Cdk4 binding to cancer-associated p16(INK4a) mutants.
- To elucidate the mechanisms by which hyperstability restores biological activity.
Main Methods:
- Computational prediction of stabilizing substitutions using four different techniques.
- Site-directed mutagenesis to introduce stabilizing substitutions into p16(INK4a).
- Biophysical characterization including stability assays, structural analysis, and Cdk4 binding studies.
Main Results:
- A hyperstable p16(INK4a) variant was created, 1.4 kcal/mol more stable than wild-type, with restored secondary/tertiary structure and Cdk4 binding.
- Stabilizing substitutions significantly restored Cdk4 binding to cancer-related mutant p16(INK4a) proteins (R24P, P81L, V126D).
- Biophysical studies revealed that hyperstable substitutions enhance mutant binding via increased secondary structure, thermostability, reduced hydrophobic surfaces, and decreased aggregation.
Conclusions:
- Increasing the thermodynamic stability of p16(INK4a) is a viable strategy to restore biological activity to defective mutants.
- Engineered hyperstable p16(INK4a) variants hold potential for cancer therapeutic development.
- The findings suggest a general approach for stabilizing other proteins with mutations that lead to loss of function.